Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to developing and commercializing new medicines for patients battling cancer, announced a new strategic direction to accelerate the advancement of certain of its clinical development programmes.
Boehringer Ingelheim and Trutino Biosciences today announced they have entered into a research collaboration and worldwide licensing agreement based on Trutino’s innovative On-Demand-Cytokine (ODC) platform.
Japan Takeda Pharmaceutical has exercised its option to acquire PvP Biologics in a deal valued at around $330m.
Novartis has signed a collaboration and licence agreement with the Drugs for Neglected Diseases initiative (DNDi) for the joint development of LXE408 as a new oral drug for the treatment of visceral leishmaniasis.
Roche Group’s member Genentech has signed a novel immuno-oncology therapies deal with biotechnology firm Bicycle Therapeutics.
British drugmaker GlaxoSmithKline (GSK) has collaborated with Chinese firm Clover Biopharmaceuticals to assess coronavirus (COVID-19) vaccine candidate with the pandemic adjuvant system.
Genetron Holding, a China-based precision oncology company that covers full-cycle cancer care, has announced a strategic partnership with Beijing InnoCare Pharma to provide clinical trial genomic testing and companion diagnostics development services for InnoCare’s biomarker-driven oncology drug development.
British drugmaker GlaxoSmithKline (GSK) has entered into a deal with Immatics Biotechnologies for the development of novel adoptive cell therapies for multiple cancer indications.
Humanetics announced that it has entered into a definitive agreement with DSM Nutritional Products Ltd of Kaiseraugst Switzerland to acquire all of DSM’s assets related to the manufacture of the active pharmaceutical ingredient (API) in BIO 300, a clinical stage drug being developed by Humanetics for oncology and biodefense applications.
ALX Oncology, a clinical-stage immuno-oncology company developing therapies to block the CD47 checkpoint mechanism, today announced the closing of a $105 million Series C equity financing.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.